<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561130</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT-Dapa</org_study_id>
    <nct_id>NCT02561130</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga</brief_title>
  <official_title>Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes, a
      short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin
      glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving
      sustained diabetes remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 152 patients with
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week
      course of treatment with Forxiga, metformin, insulin glargine and lifestyle therapy, and (b)
      standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all
      participants with HbA1C&lt;7.3% at the 12 week visit, glucose-lowering medications will be
      discontinued and participants will be encouraged to continue with lifestyle modifications and
      regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience
      hyperglycemia relapse after stopping drugs will receive standard glycemic management as
      informed by the current Canadian Diabetes Association clinical practice guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission in the experimental group compared to the control group</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free HbA1C &lt; 6.0%</measure>
    <time_frame>24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes regression</measure>
    <time_frame>24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
    <description>Diabetes regression is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C levels</measure>
    <time_frame>12 weeks, 24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hypoglycemia</measure>
    <time_frame>During 64 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>12 weeks, 24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from baseline</measure>
    <time_frame>12 weeks, 24 weeks, 36 weeks, 48 weeks and 64 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Dose is titrated to 1 g bid or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forxiga</intervention_name>
    <description>Dose is titrated to 10 mg po daily or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive;

          2. type 2 diabetes mellitus diagnosed by a physician within 8 years prior to patient
             enrollment;

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization;

          4. HbA1C 6.5-9.5% inclusive on no hypoglycemic agents or HbA1C ≤ 8.0% on up to 2
             glucose-lowering agents;

          5. body mass index ≥ 23 kg/m2;

          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);

          7. ability and willingness to self-inject insulin;

          8. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy;

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;

          3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR&lt;60
             mL/min/1.73 m2 by MDRD formula;

          4. history of lactic acidosis or diabetic ketoacidosis;

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment;

          6. history of bladder cancer or undiagnosed hematuria;

          7. history of breast cancer;

          8. history of polycythemia;

          9. evidence of volume depletion or hypotension (systolic blood pressure &lt; 90 mmHg);

         10. systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 105 mmHg;

         11. diagnosed cardiovascular disease (unless cleared for a moderate intensity exercise
             program by a specialist) including:

               1. any history of acute coronary syndrome, hospitalization for unstable angina,
                  myocardial infarction, or revascularization with coronary artery bypass grafting
                  or percutaneous coronary intervention;

               2. other evidence of coronary artery disease;

               3. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic
                  dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA;

               4. prior hospitalization for heart failure; or

               5. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,
                  ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock,
                  left bundle branch block, second or third degree atrioventricular block).

         12. dependence on oxygen;

         13. history of any disease requiring frequent intermittent or continuous systemic
             glucocorticoid treatment;

         14. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;

         15. history of any major illness with a life expectancy of &lt; 3 years;

         16. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity;

         17. any history of excessive alcohol intake, acute or chronic;

         18. currently pregnant, or breastfeeding, or not using a reliable method of birth control
             for the duration of the trial in all females with childbearing potential; reliable
             methods of birth control include oral contraceptive (birth control pill), hormonal
             injection, implant, patch, or vaginal ring, intrauterine device, barrier method
             (condom and spermicide), tubal ligation, partner vasectomy or abstinence;

         19. known hypersensitivity to metformin, Forxiga, or insulin glargine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia McInnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel C Gerstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michaels's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <keyword>Metformin</keyword>
  <keyword>Forxiga</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

